← Leaderboards
Alex Kentsis
Dana-Farber Cancer Inst
$10,070,317
Attributed
$11,028,328
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,531,836 · 5
FDA$1,496,492 · 1
By mechanism
R01$7,719,365 · 2
U01$1,496,492 · 1
R21$1,044,538 · 2
K08$767,933 · 1
Top collaborators
- Jarrod A. Marto2 shared
- Andrew William Mcpherson1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Xiaofeng Wang$2,865,626
- Hugo Aerts$3,643,476
- Cigall Kadoch$10,191,824
- Katja Gabriele Weinacht$3,414,687
- Alejandro Gutierrez$7,788,333
Others in their field
Top investigators on “Genetic”
- Richard A Gibbs · Baylor College Of Medicine$577,061,667
- Eric S Lander · Whitehead Institute For Biomedical Res$560,806,052
- David R. Weir · University Of Michigan At Ann Arbor$322,225,557
- Richard K. Wilson · Washington University$316,685,275
- Lawrence Corey · Fred Hutchinson Cancer Center$312,182,347
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$302,429,647
Research focus
GeneticMolecularSignal TransductionResistanceCellsInsightRefractoryInnovationPathway InteractionsChildMutationAdultMalignant NeoplasmsPublic HealthMissionOncogenicUnited States National Institutes Of HealthGenomicsResearch Project GrantsGenesChemotherapyBaseBiologicalCell Growth
Grant awards (28)
ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA$508,054
R01 · FY2025 · CA · contact PI
Integrative proteogenomics for elucidation of tumor-specific cell surface proteomes in ultra-rare cancers$1,496,492
U01 · FY2024 · FD · contact PI
ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA$473,190
R01 · FY2024 · CA · contact PI
ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA$478,557
R01 · FY2023 · CA · contact PI
Structure and function of genome plasticity in human cancer$509,506
R01 · FY2022 · CA · contact PI
ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA$469,177
R01 · FY2022 · CA · contact PI
Structure and function of genome plasticity in human cancer$519,902
R01 · FY2021 · CA · contact PI
ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA$469,946
R01 · FY2021 · CA · contact PI
Multi-dimensional targeted mass spectrometry technology for pathway-scale functional proteomics$195,315
R21 · FY2021 · CA · contact PI
Structure and function of genome plasticity in human cancer$519,902
R01 · FY2020 · CA · contact PI
Aberrant signaling in acute myeloid leukemia$481,665
R01 · FY2020 · CA · contact PI
Multi-dimensional targeted mass spectrometry technology for pathway-scale functional proteomics$195,315
R21 · FY2020 · CA · contact PI
Structure and function of genome plasticity in human cancer$482,122
R01 · FY2019 · CA · contact PI
Aberrant signaling in acute myeloid leukemia$467,215
R01 · FY2019 · CA · contact PI
Multi-dimensional targeted mass spectrometry technology for pathway-scale functional proteomics$234,378
R21 · FY2019 · CA · contact PI
Structure and function of genome plasticity in human cancer$497,179
R01 · FY2018 · CA · contact PI
Aberrant signaling in acute myeloid leukemia$459,674
R01 · FY2018 · CA · contact PI
Aberrant signaling in acute myeloid leukemia$231,795
R01 · FY2018 · CA · contact PI
Aberrant signaling in acute myeloid leukemia$459,674
R01 · FY2017 · CA · contact PI
Aberrant signaling in acute myeloid leukemia$232,133
R01 · FY2017 · CA · contact PI
Aberrant signaling in acute myeloid leukemia$459,674
R01 · FY2016 · CA · contact PI
Phosphoproteomic signatures for early detection and stratification of AML$190,852
R21 · FY2016 · CA
Phosphoproteomic signatures for early detection and stratification of AML$228,678
R21 · FY2015 · CA
Aberrant activation of HGF/MET signaling as a therapeutic target in AML$156,330
K08 · FY2015 · CA · contact PI
Aberrant activation of HGF/MET signaling as a therapeutic target in AML$156,330
K08 · FY2014 · CA · contact PI
Aberrant activation of HGF/MET signaling as a therapeutic target in AML$156,330
K08 · FY2013 · CA · contact PI
Aberrant activation of HGF/MET signaling as a therapeutic target in AML$142,613
K08 · FY2012 · CA · contact PI
Aberrant activation of HGF/MET signaling as a therapeutic target in AML$156,330
K08 · FY2011 · CA · contact PI